[Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)

被引：0
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 9
页数：3
相关论文
共 6 条
[1]  
[Anonymous], 2019, N ENGL J MED
[2]  
Krop I, 2019, 2019 SAN ANT BREAST
[3]   The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy [J].
Nakada, Takashi ;
Sugihara, Kiyoshi ;
Jikoh, Takahiro ;
Abe, Yuki ;
Agatsuma, Toshinori .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (03) :173-185
[4]   DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 [J].
Ogitani, Yusuke ;
Aida, Tetsuo ;
Hagihara, Katsunobu ;
Yamaguchi, Junko ;
Ishii, Chiaki ;
Harada, Naoya ;
Soma, Masako ;
Okamoto, Hiromi ;
Oitate, Masataka ;
Arakawa, Shingo ;
Hirai, Takehiro ;
Atsumi, Ryo ;
Nakada, Takashi ;
Hayakawa, Ichiro ;
Abe, Yuki ;
Agatsuma, Toshinori .
CLINICAL CANCER RESEARCH, 2016, 22 (20) :5097-5108
[5]   Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study [J].
Tamura, Kenji ;
Tsurutani, Junji ;
Takahashi, Shunji ;
Iwata, Hiroji ;
Krop, Ian E. ;
Redfern, Charles ;
Sagara, Yasuaki ;
Doi, Toshihiko ;
Park, Haeseong ;
Murthy, Rashmi K. ;
Redman, Rebecca A. ;
Jikoh, Takahiro ;
Lee, Caleb ;
Sugihara, Masahiro ;
Shahidi, Javad ;
Yver, Antoine ;
Modi, Shanu .
LANCET ONCOLOGY, 2019, 20 (06) :816-826
[6]  
US Food and Drug Administration, FDA APPR FAM TRAST D
1